ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "🎙️ Episode 30: PAD Progress: Low-Dose Rivaroxaban Gets the Green Light"
Episode Synopsis
Send us a text🧪 VOYAGER-PAD Trial:Patients with PAD post lower extremity revascularization.Rivaroxaban 2.5 mg BID + aspirin vs aspirin alone.📈 Results:↓ Major Adverse CV Events (MACE).↓ Major Adverse Limb Events (MALE).Modest ↑ in bleeding — no ↑ in fatal bleeds.🧩 Clinical Takeaway:Now guideline-endorsed for symptomatic PAD post-intervention.Risk-benefit conversation needed in high-bleed-risk patients.
In God we trust